The GLP is committed to full transparency. Download and review our Annual Report.

Investigational Alzheimer’s drug shows promise

| | August 7, 2018

An investigational Alzheimer’s drug significantly slowed patients’ cognitive decline in a large clinical trial, unexpected and unprecedented results that could move the treatment’s makers to roll the dice on an early approval.

In the study, the highest-tested dose of a drug from Biogen and Eisai was markedly better than placebo at delaying the memory-destroying effects of Alzheimer’s. After 18 months, patients who got the drug, called BAN2401, performed 30 percent better on a cognitive test than those getting placebo.

But there are caveats. Four doses of BAN2401 didn’t outperform placebo [in the Phase 2 trial], and the high dose was tested on just 161 patients. Furthermore, the metric Biogen and Eisai used to measure mental acuity is a homegrown composite that has never before been used to win Food and Drug Administration approval.

Related article:  Drug reverses aging — in rats. Could it help humans?

Biogen and Eisai have not said whether they will take up a larger study to tease out BAN2401’s benefits or go straight to the FDA with the Phase 2 results.

It’s unclear whether the FDA will lower the traditionally high bar set for Alzheimer’s therapies, which have in the past needed two Phase 3 trials to merit approval.

Read full, original post: Experimental Alzheimer’s drug significantly slowed patients’ cognitive decline, buoying hopes for treatment (Behind paywall)

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend